Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Dermatol. 2001 Dec;137(12):1597-604.

Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks.

Author information

1
Department of Dermatology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. swkang@umich.edu

Abstract

OBJECTIVE:

To assess the safety and efficacy of 4 concentrations of tazarotene cream in the treatment of facial photodamage.

DESIGN:

Prospective weekly multicenter, investigator-masked, randomized, parallel-group study.

SETTING:

University hospitals and clinical research centers.

PATIENTS:

Three hundred forty-nine subjects with facial photodamage.

INTERVENTION:

Daily topical application of tazarotene cream (0.01%, 0.025%, 0.05%, and 0.1%) compared with its vehicle and with 0.05% tretinoin emollient cream.

RESULTS:

Tazarotene cream and tretinoin cream significantly improved mottled hyperpigmentation and fine wrinkles. At week 24, treatment success rates based on global responses were 67% (39 of 58 subjects) with 0.1% tazarotene, 52% (30 of 58 subjects) with 0.05% tazarotene, 36% (21 of 58 subjects) with 0.025% tazarotene, 41% (24 of 59 subjects) with 0.01% tazarotene, 55% (32 of 58 subjects) with 0.05% tretinoin, and 22% (13 of 58 subjects) with vehicle. Local adverse events, although more frequent with tazarotene at higher concentrations, were generally mild to moderate.

CONCLUSIONS:

Tazarotene in a cream formulation is safe and is associated with positive changes in the treatment of photodamaged facial skin.

PMID:
11735710
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center